Comparison of the injection-site experience of the starting doses with semaglutide and dulaglutide: A randomized, double-blind trial in healthy subjects.
Quick Facts
What This Study Found
Key Numbers
How They Did This
Why This Research Matters
What This Study Doesn't Tell Us
Trust & Context
- Original Title:
- Comparison of the injection-site experience of the starting doses with semaglutide and dulaglutide: A randomized, double-blind trial in healthy subjects.
- Published In:
- Diabetes, obesity & metabolism, 23(6), 1415-1419 (2021)
- Database ID:
- RPEP-05777
Evidence Hierarchy
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-05777APA
Snitker, Søren; Andersen, Andreas; Berg, Birgitte; van Marle, Sjoerd; Sparre, Thomas. (2021). Comparison of the injection-site experience of the starting doses with semaglutide and dulaglutide: A randomized, double-blind trial in healthy subjects.. Diabetes, obesity & metabolism, 23(6), 1415-1419. https://doi.org/10.1111/dom.14349
MLA
Snitker, Søren, et al. "Comparison of the injection-site experience of the starting doses with semaglutide and dulaglutide: A randomized, double-blind trial in healthy subjects.." Diabetes, 2021. https://doi.org/10.1111/dom.14349
RethinkPeptides
RethinkPeptides Research Database. "Comparison of the injection-site experience of the starting ..." RPEP-05777. Retrieved from https://rethinkpeptides.com/research/snitker-2021-comparison-of-the-injectionsite
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.